All sessions are listed in Eastern Time. 

Plenary Symposia

  • Date:
  • Time: -
  • Track: Research
  • CME/CE: 1
  • Q & A: Video

Co-Moderators: Esther S. Oh, MD, PhD & Noll L. Campbell, PharmD, MS
Sponsored by the Clinical Research in Dementia Special Interest Group

This program is intended to provide information for health professionals who want to learn more about the anti-amyloid monoclonal antibody (mab) for treatment of early symptomatic Alzheimer’s disease (AD) with focus on lecanemab. Presenters will also discuss donanemab if it is FDA approved by May 2024. Learning Objectives: (1) discuss the evidence and controversies surrounding the new mab AD medications, and how best to choose appropriate patient population, determine therapeutic dose/frequency/duration and monitor for adverse events; (2) review CMS’s approach to addressing access to FDA approved medications and FDA cleared diagnostics, for Medicare beneficiaries with Alzheimer’s disease; (3) describe the current brain health inequities in the United States and how beta anti-amyloid monoclonal antibody treatment will exacerbate these inequities without additional changes to our AD/ADRD prevention, diagnosis and care paradigms; and (4) discuss the healthcare delivery and economic implications of the FDA approval of medications, such as lecanemab, that target a broad population of people at risk or with Alzheimer’s disease.

Use of Anti-Amyloid Therapy for Alzheimer’s Disease in Clinical Practice
Esther S. Oh, MD, PhD
Coverage of FDA Approved Medications and FDA Cleared Diagnostics for Medicare Beneficiaries with Alzheimer’s Disease
Shari M. Ling, MD
It’s Not Just the $26,500: How Existing Brain Health Inequities Will Be Exacerbated by Beta Anti-Amyloid Monoclonal Antibody Treatment and Real-World Opportunities and Solutions to Address These Challenges
Abraham A. Brody, PhD, RN, FAAN
Population and Economic Implications Treatment of People with or at Risk for Alzheimer’s Disease
Julie Bynum, MD, MPH